Table 1.
Baseline characteristics of the Lp(a) and LDL-C cohorts.
| Lp(a) Cohort | LDL Cohort | |
|---|---|---|
| Characteristic | (N=20551) | (N=82204) |
| Demographics | ||
| Age (years) | 58 (47, 67) | 54 (41, 65) |
| Female | 10094 (49.1%) | 45750 (55.7%) |
| Race | ||
| Black or African American | 1498 (7.3%) | 7632 (9.3%) |
| White | 17357 (84.5%) | 67123 (81.7%) |
| Other | 1697 (8.3%) | 7449 (9.0%) |
| Hispanic Ethnicity | 577 (2.8%) | 2974 (3.6%) |
| Setting of Index Lab | ||
| Inpatient | 2145/10864 (19.7%) | 3213/46561 (6.9%) |
| Outpatient | 8647/10864 (79.6%) | 43140/46561 (92.7%) |
| Other/Unknown | 72/10864 (0.7%) | 208/46561 (0.4%) |
| Insurance | ||
| Public (Medicare/Medicaid) | 2546 (25.3%) | 8901 (20.7%) |
| Private Health Insurance | 3237 (32.2%) | 10303 (24.0%) |
| Self-Pay/No Payment | 647 (6.4%) | 2261 (5.3%) |
| Other/Unknown | 3626 (36.1%) | 21505 (50.0%) |
| Year of Index Test | ||
| 2015 | 3295 (16.0%) | 13180 (16.0%) |
| 2016 | 3703 (18.0%) | 14812 (18.0%) |
| 2017 | 3877 (18.9%) | 15508 (18.9%) |
| 2018 | 4391 (21.4%) | 17564 (21.4%) |
| 2019 | 5285 (25.7%) | 21140 (25.7%) |
| Site Region | ||
| Midwest | 12372 (60.2%) | 49488 (60.2%) |
| Northeast | 3570 (17.4%) | 14280 (17.4%) |
| South | 4609 (22.4%) | 18436 (22.4%) |
| Comorbidities | ||
| Hypertension | 9343 (45.5%) | 31025 (37.7%) |
| Hyperlipidemia | 13220 (64.3%) | 27587 (33.6%) |
| Diabetes | 3481 (16.9%) | 12004 (14.6%) |
| MI | 2066 (10.1%) | 3070 (3.7%) |
| MI within 3 Months of Index Lab | 1460 (7.1%) | 2010 (2.4%) |
| MI within 12 Months of Index Lab | 1797 (8.7%) | 2476 (3.0%) |
| Coronary Revascularization | 2478 (12.1%) | 3379 (4.1%) |
| Revascularization within 3 Months of Index Lab | 656 (3.2%) | 701 (0.9%) |
| Revascularization within 12 Months of Index Lab | 970 (4.7%) | 861 (1.0%) |
| Ischemic Stroke | 2237 (10.9%) | 2620 (3.2%) |
| Stroke within 3 Months of Index Lab | 1951 (9.5%) | 2041 (2.5%) |
| Stroke within 12 Months of Index Lab | 2076 (10.1%) | 2275 (2.8%) |
| Hemorrhagic Stroke | 281 (1.4%) | 467 (0.6%) |
| CAD | 6543 (31.8%) | 9915 (12.1%) |
| TIA | 716 (3.5%) | 1034 (1.3%) |
| PAD | 3018 (14.7%) | 6199 (7.5%) |
| Stage 3 and 4 CKD | 1123 (5.5%) | 4179 (5.1%) |
| Cancer | 419 (2.0%) | 1575 (1.9%) |
| Multiple CV Events | 1771 (8.6%) | 2122 (2.6%) |
| Labs and Vitals | ||
| Systolic Blood Pressure | 125 (114, 137) | 124 (114, 136) |
| Diastolic Blood Pressure | 76 (69, 82) | 76 (69, 82) |
| Body Mass Index | 28 (25, 32) | 29 (25, 34) |
| Current Smoker | 1492/16008 (9.3%) | 9035/65956 (13.7%) |
| eGFR ≤ 60 mL/min/1.73m2 | 8682 (47.4%) | 29874 (43.7%) |
| Total Cholesterol | 184 (150, 223) | 182 (155, 210) |
| High Density Lipoprotein | 50 (40, 64) | 52 (42, 66) |
| Low Density Lipoprotein | 103 (76, 136) | 102 (80, 127) |
| Triglycerides | 111 (78, 165) | 107 (76, 156) |
| Medication History | ||
| Statin Monotherapy | 9140 (44.5%) | 19129 (23.3%) |
| Statin + Ezetimibe Combination Therapy | 1047 (5.1%) | 503 (0.6%) |
| Ezetimibe Monotherapy | 261 (1.3%) | 235 (0.3%) |
| PCSK9i | 380 (1.8%) | 47 (0.1%) |
| Niacin | 712 (3.5%) | 1960 (2.4%) |
| Other Lipid Lowering Therapy | 1153 (5.6%) | 2299 (2.8%) |
| ACEi/ARB | 6331 (30.8%) | 19132 (23.3%) |
| Beta Blocker | 6153 (29.9%) | 16018 (19.5%) |
| Anticoagulant | 2996 (14.6%) | 3350 (4.1%) |
| Other Blood Pressure Medication | 6961 (33.9%) | 22597 (27.5%) |
| Aspirin | 7695 (37.4%) | 14745 (17.9%) |
| Any LLT | 10738 (52.3%) | 21104 (25.7%) |
Abbreviations: Angiotensin Converting Enzyme inhibitor, ACEi; Angiotensin Receptor Blocker, ARB; Coronary Artery Disease, CAD; Chronic Kidney Disease, CKD; Cardiovascular, CV; Estimated Glomerular Filtration Rate, eGFR; Lipid Lowering Therapy, LLT; Myocardial infarction, MI; Peripheral Artery Disease, PAD; Proprotein convertase subtilisin/kexin type 9 inhibitor, PCSK9i; Transient Ischemic Attack, TIA.